secwatch.observer — SEC 8-K summary
======================================

Issuer:     Renalytix plc (RNLXY)
CIK:        0001811115
Form:       8-K/A
Filed at:   2024-11-19T23:59:59+00:00
Accession:  0001213900-24-100211
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Renalytix raises £11.6M in private placement and restructures $11.7M convertible bonds
--------------------------------------------------------------------------------

- Gross proceeds of £2.16M from first tranche (24M shares) and £9.43M from second tranche (104.7M shares) at £0.09 per share.
- Insiders acquired 14.86M shares; all insider shares subject to six-month lock-in.
- £2.97M of bonds converted to 33M shares; remaining balance restructured as 5.5%/7.5% convertible loan note due July 2029, conversion at 250% of Issue Price.
- $850k advisor accounts payable restructured: $425k converted to shares at Issue Price; $325k to unsecured note at 5% due in 5 years or change of control.
- Net proceeds used for sales/marketing, general corporate expenses, and ~10% for EHR integrations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811115/000121390024100211/0001213900-24-100211-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811115/000121390024100211/ea0221641-8ka1_renalytix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-100211

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer